Thomas Strüngmann: Difference between revisions
A bit of adjustment Tags: Visual edit Mobile edit Mobile web edit |
No edit summary Tags: Visual edit Mobile edit Mobile web edit |
||
| Line 1: | Line 1: | ||
{{Short description|German billionaire}} |
{{Short description|German billionaire investor, businessman, and entrepreneur}} |
||
'''Thomas Strüngmann''' (born 1950) is a German billionaire [[investor]], [[businessman]], and entrepreneur. He has built his fortunes with his life-long partner and [[identical twin]], [[Andreas Strüngmann]], mainly through his success in the [[biotechnology]] and [[pharmaceutical]] sectors. Based at his single [[family office]], Athos KG, Thomas manages, together with his brother, their total family assets expected to be worth roughly $30 billion, which positions the brothers among the wealthiest Germans.<ref>{{Cite news |date=2022-02-01 |title=Ex-Head of Family Office for $31 Billion Fortune Builds Firm |url=https://www.bloomberg.com/news/articles/2022-02-01/ex-head-of-family-office-for-31-billion-fortune-builds-own-firm |access-date=2024-08-26 |work=Bloomberg.com |language=en}}</ref> |
'''Thomas Strüngmann''' (born 1950) is a German billionaire [[investor]], [[businessman]], and entrepreneur. He has built his fortunes with his life-long partner and [[identical twin]], [[Andreas Strüngmann]], mainly through his success in the [[biotechnology]] and [[pharmaceutical]] sectors. Based at his single [[family office]], Athos KG, Thomas manages, together with his brother, their total family assets expected to be worth roughly $30 billion, which positions the brothers among the wealthiest Germans.<ref>{{Cite news |date=2022-02-01 |title=Ex-Head of Family Office for $31 Billion Fortune Builds Firm |url=https://www.bloomberg.com/news/articles/2022-02-01/ex-head-of-family-office-for-31-billion-fortune-builds-own-firm |access-date=2024-08-26 |work=Bloomberg.com |language=en}}</ref> |
||
Revision as of 08:17, 26 August 2024
Thomas Strüngmann (born 1950) is a German billionaire investor, businessman, and entrepreneur. He has built his fortunes with his life-long partner and identical twin, Andreas Strüngmann, mainly through his success in the biotechnology and pharmaceutical sectors. Based at his single family office, Athos KG, Thomas manages, together with his brother, their total family assets expected to be worth roughly $30 billion, which positions the brothers among the wealthiest Germans.[1]
Career
In 2004, Strüngmann and his twin brother Andreas – through their Santo Holding – acquired a share of 89.6 percent in Südwestbank from DZ Bank. In 2017, they sold the bank for an undisclosed price to BAWAG.[2]
In 2005, the Strüngmann brothers sold Hexal to Novartis for $6.7 billion.[3] After the sale, he joined Novartis subsidiary Sandoz as head of regional operations in Germany, the Americas and the Middle East, reporting to Sandoz's chief executive, Andreas Rummelt.[4]
In 2008, the Strüngmann brothers – through their asset management firm Athos – agreed to underwrite 25 percent of a capital increase at Conergy.[5]
Also in 2008, the Strüngmann brothers supported BioNTech with a €136.5 million seed investment in a €150 million round that enabled the founding of the company.[6] They earned $8 billion on their stake in BioNTech.[7] They own approximately 50 percent of the company as well as significant ownership in 4SC and Immatics.[3] He currently has the largest health-care earned fortune with his brother.[8]
In 2014, the Strüngmann brothers' Santo Holding and EQT AB purchased Siemens Audiology Solutions from Siemens for €2.2 billion, leading the latter to abandon plans for an initial public offering.[9]
The brothers operate out of a family office, Athos Service.[3]
See also
References
- ^ "Ex-Head of Family Office for $31 Billion Fortune Builds Firm". Bloomberg.com. 2022-02-01. Retrieved 2024-08-26.
- ^ Shadia Nasralla (17 July 2017),Austria's BAWAG PSK buys Germany's Suedwestbank Reuters.
- ^ a b c Manskar, Noah (2020-11-13). "COVID-19 vaccine hopes have made these twins $8 billion richer". New York Post. Retrieved 2021-07-13.
- ^ Heather Timmons and Tom Wright (22 February 2005), Novartis to Buy Two Makers of Generics New York Times.
- ^ Nicola Leske (20 February 2008), Conergy gets investor support for cap hike -paper Reuters.
- ^ Denise Roland (15 May 2023), ‘Biotech is the ultimate impact investment’ — family offices can’t get enough of it Financial Times.
- ^ Stupples, Benjamin (November 13, 2020). "Brothers Build $22 Billion Fortune on Hope for Covid-19 Vaccine". Bloomberg.
- ^ "Bloomberg Billionaires Index". Bloomberg.
- ^ Christopher Hughes and Olaf Storbeck (25 November 2014), SIG Deal Shows Private Equity’s Desire for Big Leveraged Buyouts in Europe New York Times.
External links
| International | |
|---|---|
| National | |
| People | |
 | This German business-related biographical article is a stub. You can help Wikipedia by expanding it. |